Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.50
Bid: 15.00
Ask: 16.00
Change: -2.50 (-13.89%)
Spread: 1.00 (6.667%)
Open: 15.50
High: 16.50
Low: 15.25
Prev. Close: 18.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: essensys loss widens; Carclo demand strong

Tue, 18th Oct 2022 22:04

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

essensys PLC - London-based software and cloud services for flexible workspace industry - In year ended July 31, pretax loss widens to GBP11.1 million from GBP2.9 million a year prior. Revenue rises to GBP23.3 million from GBP22.0 million. Administrative expenses grows to GBP24.3 million from GBP16.5 million. Chief Executive Mark Furness says period was a year of "progress and resilience". "Momentum with strategic customers remains and underpins a significant pipeline of opportunities. The quality of our customer base has helped us to manage near-term headwinds such as delays to sales cycles and capital deployment, some portfolio rebalancing among our larger flexible workspace operators and the expected churn at the tail-end of our customer base," he adds.

----------

Carclo PLC - West Yorkshire-based plastic parts manufacturer - Says demand in first six months of its financial year, ending March 31 2023, has been "strong", resulting in sales marginally ahead of board expectations and ahead of the prior year. It adds: "The inflation and supply chain challenges experienced in the first half are expected to continue through the remainder of the financial year. Our initiatives to further enhance operational efficiency and to offset inflationary price increases are key focus areas for the second half. Increases in borrowing costs are expected in the second half driven by increases in both the level of debt and interest rates."

----------

Angle PLC - Surrey, England-based medical diagnostics company - Decides to close facilities in Toronto, Canada in an orderly wind down. Notes it retains its high-specification clinical laboratory facility in Plymouth Meeting, Pennsylvania, US, as its central hub for North American activities. Says decision is part of commitment to tightly control costs and focus on near-term commercialisation of Parsortix system for cancer liquid biopsy. Hopes to reduce costs by GBP2.6 million in 2023, rising to GBP4.0 million after.

----------

Aptamer Group PLC - York, England-based provider of custom services, diagnostics and therapeutics for biotechnology and pharmaceutical firms - Pretax loss in year to June narrows to GBP2.6 million versus GBP2.9 million loss in 15 months to June 30, 2021. Revenue multiplies to GBP4.0 million from GBP1.6 million. Administrative expenses rise to GBP4.4 million from GBP3.1 million. Chief Executive Arron Tolley says: "Aptamer has maintained a solid pace of progress over the past year, having seen success in both expanding current partnerships and winning new contracts. Commercial traction continues to increase in Europe, US and APAC regions." Sees strong revenue growth in current financial year.

----------

Open Orphan PLC - London-based research organisation testing infectious and respiratory disease products - Appoints Stephen Pinkerton as chief financial officer, to replace Leo Toole who will step down at end of 2022. Pinkerton is chartered accountant with over 25 years of experience in senior financial roles and has served as Commercial Financial Director of hVIVO since July 2017. Also notes Cathal Friel is reverting to Non-Executive Chair after Yamin Khan appointment of chief executive officer.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
29 Aug 2019 10:57

Angle Ovarian Cancer Testing Platform Study Enrols First Patients

(Alliance News) - Liquid biopsy firm Angle PLC said Thursday the first patients for its ovarian cancer test study have been enrolled ahead of anticipated completion early in 2020.The study

Read more
29 Aug 2019 09:12

Angle initiates main phase of ovarian cancer clinical study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the main phase of its 200-patient ovarian cancer clinical verification study has been initiated and the first patient has been enrolled.

Read more
22 Jul 2019 12:53

Angle's Parsortix Used For Analysis Of Circulating Tumor Cells

(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done to develop a "robust, reliable and for of

Read more
25 Jun 2019 08:16

Angle looks to strengthen balance sheet and extend runway via placement

(Sharecast News) - Liquid biopsy company Angle will look to raise up £18m at 61.5p per ordinary share through finnCap and WG Partners in order to strengthen its balance sheet and enable the development of key products.

Read more
21 Jun 2019 15:26

Angle upbeat on recent cancer research results

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the University Medical Centre Hamburg-Eppendorf (UKE) cancer centre has published results of work demonstrating that its 'Parsortix' system can be used as a liquid biopsy to investigate programmed death-ligand 1 (PD-L1) status in non small cell lung cancer (NSCLC) patients.

Read more
21 Jun 2019 12:56

Angle's Parsortix Successfully Investigates Immunotherapy Target

(Alliance News) - Angle PLC on Friday said its Parsortix system has been successfully used as a liquid biopsy to investigate an immunotherapy target in lung cancer.Shares in Angle were up a

Read more
5 Jun 2019 13:04

Angle's Parsortix And HyCEAD Ziplex Systems Identify Cancer In Study

LONDON (Alliance News) - Angle PLC on Wednesday announced positive results from a study evaluating the ability of its Parsortix and HyCEAD Ziplex platforms to test for ovarian cancer.The to

Read more
31 May 2019 09:53

Angle reveals positive results from latest Parsortix study

(Sharecast News) - Liquid biopsy company Angle announced positive results from its 'Parsortix' FDA clinical study for metastatic breast cancer on Friday.

Read more
26 Apr 2019 12:48

Angle's Parsortix system used in more groundbreaking research

(Sharecast News) - Liquid biopsy company Angle announced on Friday that its 'Parsortix' system has been utilised in further groundbreaking new cancer research, demonstrating the role of myeloid-derived suppressor cells (MDSCs) as part of large circulating tumor cell (CTC) clusters, which are 50x more likely to generate metastasis than single CTCs, for the first time.

Read more
26 Apr 2019 12:29

Angle's Parsortix System Used In Further "Groundbreaking" Research

LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said its Parsortix system has been used in "groundbreaking" cancer research.The research showed the first the time

Read more
18 Apr 2019 11:35

US Cancer Centre Uses Angle's Parsortix System For Assessments

LONDON (Alliance News) - Angle PLC on Thursday said its ParsortixTM system was used by the University of Texas MD Anderson Cancer Center to develop a new technique for assessing the metastatic of

Read more
12 Apr 2019 15:25

Angle's Parsortix to be used in new Greece study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that a leading customer has established a multi-centre study to investigate biomarkers on circulating tumor cells (CTCs), using its 'Parsortix' system, which could give advance warning of relapse in non small cell lung cancer (NSCLC).

Read more
12 Apr 2019 11:59

University Of Athens Cancer Study To Use Angle's Parsortix System

LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said a "leading" customer has set up a multi-centre study using its Parsortix system.The study is being carried out

Read more
7 Mar 2019 13:09

Angle Enrols All 400 Patients In US Breast Cancer Study For Parsortix

LONDON (Alliance News) - Angle PLC on Thursday said it has completed enrolment for a US study of its Parsortix biopsy technology in metastatic breast cancer.All of the 400 subjects required

Read more
7 Mar 2019 09:35

Angle completes enrolment in Parsortix breast cancer study

(Sharecast News) - Liquid biopsy company Angle announced on Thursday that enrolment for its 'Parsortix' FDA clinical study for metastatic breast cancer was now complete.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.